SBIR/STTR Research Award

Oleocanthal functional food products for breast cancer recurrence control

Award identifier 5c2a8decd61efb3957654036646f053867f903e6817b49b658f1af937e94f00dAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$454,755

Program and phase

STTR · Phase I

Award year

2020

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Oleolive, Inc.
Proposal award date
2020-06-01
Contract end date
2022-05-31
UEI
DSBCG7NS87J3
Solicitation number
PA18-837
Topic code
102

Research abstract

SUMMARY From Parent Grant (R41CA247025) Triple negative breast cancer (TNBC) represents 20% of the breast cancer (BC) cases in the US. TNBC patients have a poor recurrence-free, overall survival rate, and limited available treatment options. The Mediterranean olive oil-rich diet is documented to reduce BC incidence. (-)-Oleocanthal (OC) is a natural phenolic secoiridoid exclusively occurring in extra-virgin olive oil (EVOO) and it has shown selective anti-BC activities, including preliminary results showing prevention of recurrence of TNBC in animal models. The HGF/Met signaling pathway, a validated major OC molecular target, is likely involved in initiating aggressive and recurrent TNBC in a subset of patients. To improve taste, dissolution and stability, a solid dispersion formulation of OC (OC-X) was recently developed and characterized. We hypothesize that the EVOO powdered formulation of OC, OC-X, could be developed as a nutraceutical product to help control locoregional TNBC recurrence. This will be tested in the following Specific Aims. In the first aim, we will perform dose dependent studies to determine the optimal effective dose of orally administered OC-X on tumor recurrence in a nude mouse model after primary tumor surgical resection. This aim will assess the efficacy of formulations in preventive, treatment, and after completion of paclitaxel neoadjuvant regimen modes. In the second aim, we will perform dose dependent studies to determine the optimal effective dose of orally administered OC-X on tumor recurrence in the MMTV-PyMT transgenic mouse model. This immune competent mouse model develops BC mimicking progression seen in human patients and will be used to assess BC recurrence (after surgical excision of early mammary gland tumors) and metastasis following treatment with OC-X. Expected outcomes: EVOO enriched in OC has been safely consumed throughout human history with increasing evidence of effectiveness against many human pathologies, including BC. Given the lack of other safe therapeutic alternatives, OC is a candidate bioactive natural product that could be safe for long-term use to prevent BC recurrence. The data generated by this project will be combined with future studies of OC-X to facilitate commercialization of OC-X as a nutraceutical product to prevent BC recurrence.PROJECT NARRATIVE From Parent Grant (R41CA247025) Triple negative breast cancer patients have poor recurrence-free and overall survival rates, and therapeutic options are limited. Preliminary studies validated the olive oil phenolic oleocanthal as potential natural product to control breast cancer. The proposed project will test the efficacy of a proprietary powder formulation of oleocanthal in preventing or slowing triple negative breast cancer progression and recurrence in two distinct and relevant mouse models.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

8 SBIR/STTR records share this UEI (2018–2025). Reported award amounts total $5,248,395. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.